A phase I study of FLX925, a dual FLT3 and CDK4/6 inhibitor in patients with relapsed or refractory acute myeloid leukemia (AML) Meeting Abstract
| Authors: | Daver, N.; Pollyea, D. A.; Rizzieri, D. A.; Palmer, J.; Rampal, R. K.; Dinner, S.; Bixby, D. L.; Percival, M. E. M.; Kovacsovics, T.; Begna, K. H.; Perl, A. E.; Konopleva, M.; Seitz, L.; McKinnell, J.; Johnson, D. T.; Ho, W.; Cortes, J. E. |
| Abstract Title: | A phase I study of FLX925, a dual FLT3 and CDK4/6 inhibitor in patients with relapsed or refractory acute myeloid leukemia (AML) |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419403167 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.1343.1343 |
| Notes: | Meeting Abstract: 1343 -- Source: Wos |
